TCF4 and CtBP1 Repress LEF1 to Maintain a TCF4-centric Transcriptional Program in Colon Cancer.
In colon cancer, TCF4 maintains a stem cell-like transcriptional program by directly repressing LEF1 via CtBP1, thereby preventing LEF1 from driving immune-related gene signatures and ensuring the expression of MYC and cell cycle genes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human body, the intestines are a bustling landscape of renewal. Every day, the lining of the colon is replaced by fresh cells, a process driven by a small population of stem cells that act as the source of new tissue. These stem cells rely on a specific chemical signal, known as the WNT pathway, to know when to divide and when to stay put. This signal works like a switch: when it is turned on, it tells the cell to grow; when it is off, the cell rests. In a healthy adult, this system is tightly controlled, ensuring that the colon maintains its proper size and function without growing out of control. However, when this switch gets stuck in the "on" position, it can lead to the uncontrolled growth that characterizes colon cancer. For decades, scientists have understood that this pathway is central to the disease, but the precise mechanics of how different parts of the system interact within a cancer cell have remained somewhat mysterious.
In a new study, researchers set out to understand the specific roles of the molecular players that carry this growth signal. They focused on a group of proteins that act as the final messengers, reading the signal and turning on the genes that tell the cell to divide. One of these proteins, TCF4, is known to be the primary driver in the healthy colon. Another, LEF1, is usually quiet in the adult gut but becomes more active in cancer. The central question was simple: in a cancer cell where the growth signal is constantly active, how do these two proteins coexist, and do they work together or against each other? The researchers discovered that TCF4 does not just drive growth; it also acts as a gatekeeper, actively suppressing LEF1 to keep the cell's behavior focused. When this gatekeeper is removed, the cell's internal program shifts dramatically, revealing a hidden layer of regulation that could change how we think about cancer development.
To investigate this, the team worked with colon cancer cells grown in the laboratory. They began by silencing the gene that produces TCF4, effectively turning off the main driver of the growth signal. They expected that without TCF4, the cells would simply stop growing or behave erratically. Instead, they observed a surprising reaction. As the levels of TCF4 dropped, the levels of LEF1 rose sharply, increasing nearly threefold. This suggested that TCF4 was actively holding LEF1 in check. To confirm that this increase in LEF1 was not just a random side effect, the researchers checked if the new LEF1 protein was actually functional. They found that it was fully capable of turning on the same growth genes as TCF4, meaning the cell had swapped one growth engine for another.
The team then looked deeper to understand how TCF4 was keeping LEF1 suppressed. They identified a partner protein called CtBP1, which acts as a repressor, or a silencer, of gene activity. They found that TCF4 recruits CtBP1 to the specific spot in the DNA where the LEF1 gene is located. Together, they bind to the gene and turn it off. When the researchers silenced CtBP1, LEF1 levels also rose, though not as dramatically as when TCF4 was removed. This indicated that TCF4 and CtBP1 work as a team to keep LEF1 quiet. The researchers confirmed this direct interaction by mapping the physical locations where these proteins bind to the DNA, finding clear evidence that they sit right on top of the LEF1 gene to prevent it from being read.
The study also revealed that these two proteins, TCF4 and LEF1, do not just drive growth in the same way; they steer the cell toward different destinations. When TCF4 is present, the cell focuses on a program that drives rapid cell division and the production of a protein called MYC, which is a well-known accelerator of cancer growth. However, when TCF4 is removed and LEF1 takes over, the cell's behavior changes. The genes that are turned on shift away from pure cell division and toward a program involving the immune system. The cells begin to express genes associated with inflammation and immune responses, suggesting that LEF1 changes the identity of the cancer cell, making it more visible to the body's defenses or altering its environment.
The researchers also tested whether the specific genetic mutations that cause colon cancer, particularly those in a protein called APC, were responsible for this switch between TCF4 and LEF1. They found that the presence or absence of these mutations did not determine whether LEF1 would rise when TCF4 was silenced. Instead, the relationship between TCF4 and LEF1 appeared to be a fundamental rule of how these cells operate, independent of the initial cause of the cancer. In some cell lines, LEF1 was naturally absent, and silencing TCF4 did not bring it back, suggesting that the ability to switch depends on the specific history of the cell.
Ultimately, the study paints a picture of a delicate balance within the cancer cell. TCF4 is not merely a switch that turns growth on; it is also a regulator that suppresses an alternative program driven by LEF1. By recruiting a silencer protein, TCF4 ensures that the cell remains focused on the specific type of growth that characterizes the cancer it has become. When this control is lost, the cell does not simply stop; it reprograms itself, activating a different set of genes that could alter how the cancer behaves and how it interacts with the immune system. This discovery highlights that the proteins driving cancer are not just simple on/off switches but complex regulators that maintain a specific cellular identity, and disrupting that identity can lead to unexpected changes in the disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.